"NEXT Oncology specializes in providing clinical trial therapies to cancer patients. NEXT can also provide second opinions and standard therapies if needed."

During the past decade, NEXT Oncology conducted 128 clinical trials. In the 10-year time frame, 128 clinical trials started and 4 clinical trials were completed, i.e. on average, 3.1% percent of trials that started reached the finish line to date. In the past 5 years, 104 clinical trials started and 4 clinical trials were completed. i.e. 3.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "NEXT Oncology" #1 sponsor was "Pfizer" with 9 trials, followed by "EMD Serono Research & Development Institute, Inc." with 6 trials sponsored, "Gilead Sciences" with 6 trials sponsored, "Adagene Inc" with 5 trials sponsored and "Mirati Therapeutics Inc." with 5 trials sponsored. Other sponsors include 92 different institutions and companies that sponsored additional 83 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "NEXT Oncology" #1 collaborator was "Merck Sharp & Dohme LLC" with 9 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 6 trials as a collaborator, "AstraZeneca" with 3 trials as a collaborator, "AbbVie" with 2 trials as a collaborator and "Seven and Eight Biopharmaceuticals Inc" with 2 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "NEXT Oncology" are "Solid Tumor" (20 trials), "Advanced Solid Tumor" (17 trials), "Advanced Solid Tumors" (14 trials), "Colorectal Cancer" (12 trials) and "Melanoma" (11 trials). Many other conditions were trialed in "NEXT Oncology" in a lesser frequency.

Most popular intervention types in "NEXT Oncology" are "Drug" (116 trials), "Biological" (14 trials), "Combination Product" (2 trials), "Diagnostic Test" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (11 trials), "Carboplatin" (4 trials), "Gemcitabine" (4 trials), "ADG116" (3 trials) and "MRTX849" (3 trials). Other intervention names were less common.

The vast majority of trials in "NEXT Oncology" are 128 trials for "All" genders.

Currently, there are NaN active trials in "NEXT Oncology". undefined are not yet recruiting, 74 are recruiting, 22 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 16 completed trials in NEXT Oncology, undefined suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in NEXT Oncology, 126 "Phase 1" clinical trials were conducted, 35 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".

NEXT Oncology has several departments that took part in Clinical trials: "Next Oncology" - 35 trials